REGN Factor-Based Stock Analysis - Benjamin Graham June 11, 2025 — 02:05 pm EDT Written by John Reese for Validea -> ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

REGENERON PHARMACEUTICALS INC is a large-cap value stock in the Biotechnology & Drugs industry. The ... Detailed Analysis of REGENERON PHARMACEUTICALS INC. REGN Guru Analysis.

Regeneron Pharmaceuticals Inc. stock grades by Barron's. View REGN fundamental and sentiment analysis powered by MarketGrader.

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.

Regeneron’s stock crashed 17% on Friday. Meanwhile, JPMorgan downgraded Cooper Companies to ‘Neutral’ from ‘Overweight,’ lowering the price target to $76 from $110.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients.

Regeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage trials of Itepekimab, an experimental treatment for chronic obstructive ...

On this episode of Stock Movers: - Ulta Beauty (ULTA) shares leap as much as 16% on Friday, the most intraday since November 2020, after the cosmetics retailer boosted its earnings per share ...